Eisai/Biogen Maintain Lead Over Lilly In New Race To Alzheimer’s Approval

Full Approval Filing May Quickly Follow Accelerated US FDA Decision

 
• By Mandy Jackson
Up arrows on blue background illustration
Eisai/Biogen have a nearly two-month lead over Lilly • Source: Shutterstock

More from New Products

More from Scrip